Protea F.-Sec.Healthcare Opp.Fd.I USD
LU1849504565
Protea F.-Sec.Healthcare Opp.Fd.I USD/ LU1849504565 /
NAV22.08.2024 |
Zm.-0,0800 |
Typ dystrybucji dochodów |
Kategoria |
Firma inwestycyjna |
916,0400USD |
-0,01% |
z reinwestycją |
Akcje
Światowy
|
FundPartner Sol.(EU) ▶ |
Strategia inwestycyjna
The Sub-Fund invests primarily in innovative healthcare companies developing differentiated drugs, services, life science tools and devices in therapeutic areas with large unmet medical needs. Investments are made across all market caps and geographies, including the emerging markets, with significant exposure to mid- and small-cap companies, due to their high degree of innovation. Novel and differentiated treatments, devices, and services benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in healthcare delivery and novel therapeutic modalities has created new business models and markets with tremendous commercial potential.
In order to achieve this objective, the Sub-Fund invests, while respecting the principle of risk diversification, primarily in equities (including, but not limited to, common stocks, preferred stocks, or other securities convertible into common stock) and equity related securities (such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs), European Depositary Receipts (EDRs)) issued by mid and large cap issuers which are located worldwide (with a maximum exposure of 33% to emerging markets) and which are active in the following healthcare sectors: healthcare equipment and services, pharmaceuticals, biotechnology and life sciences. The Sub-Fund may, invest in transferable securities and money market instruments from new issues to benefit from particularly innovative projects in the healthcare sector. The Sub-Fund may invest up to 33% of its net assets via Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect in China A-Shares. Up to 10% of the Sub-Fund's net assets may be invested in Special Purpose Acquisition Companies. Up to 33% of the Sub-Fund's net assets may be invested outside the aforementioned investment universe including but not limited to equities of issuers of other business segments than healthcare, in fixed and variable interest securities. The Sub-Fund may not invest more than 10% of its net assets in other UCIs or UCITS.
Cel inwestycyjny
The Sub-Fund invests primarily in innovative healthcare companies developing differentiated drugs, services, life science tools and devices in therapeutic areas with large unmet medical needs. Investments are made across all market caps and geographies, including the emerging markets, with significant exposure to mid- and small-cap companies, due to their high degree of innovation. Novel and differentiated treatments, devices, and services benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in healthcare delivery and novel therapeutic modalities has created new business models and markets with tremendous commercial potential.
Dane podstawowe
Typ dystrybucji dochodów: |
z reinwestycją |
Kategoria funduszy: |
Akcje |
Region: |
Światowy |
Branża: |
Sector Health / Pharma |
Benchmark: |
MSCI TR World Net Health Care USD Index |
Początek roku obrachunkowego: |
01.07 |
Last Distribution: |
- |
Bank depozytariusz: |
Bank Pictet & Cie (Europe) AG |
Kraj pochodzenia funduszu: |
Luxemburg |
Zezwolenie na dystrybucję: |
Austria, Niemcy, Szwajcaria |
Zarządzający funduszem: |
- |
Aktywa: |
112,43 mln
USD
|
Data startu: |
31.08.2018 |
Koncentracja inwestycyjna: |
- |
Warunki
Opłata za nabycie: |
2,00% |
Max. Administration Fee: |
0,59% |
Minimalna inwestycja: |
250 000,00 USD |
Opłaty depozytowe: |
- |
Opłata za odkupienie: |
0,00% |
Uproszczony prospekt: |
Ściągnij (Wersja do wydruku) |
Firma inwestycyjna
TFI: |
FundPartner Sol.(EU) |
Adres: |
15A, avenue J. F. Kennedy, 1855, Luxemburg |
Kraj: |
Luxemburg |
Internet: |
www.group.pictet/de
|
Kraje
Republika Korei |
|
91,48% |
USA |
|
3,79% |
Dania |
|
2,79% |
Chiny |
|
0,39% |
Brazylia |
|
0,35% |
Wielka Brytania |
|
0,26% |
Malezja |
|
0,26% |
Szwajcaria |
|
0,18% |
Irlandia |
|
0,17% |
Inne |
|
0,33% |
Branże
Usługi zdrowotne |
|
93,11% |
Farmacja/biotechnologia |
|
5,43% |
Medyczne produkty i instrumenty |
|
1,32% |
Gesundheitswesen/ Informationstechnologie |
|
0,10% |
Inne |
|
0,04% |